AAPG

Ascentage Pharma Group International (AAPG) Risks & Opportunities Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-08-01

Overall Score

Financial Risk

Leverage remains manageable with net debt to EBITDA at 0.44x and a current ratio of 1.79x.

Liquidity is supported by cash per share of 26.69 and a cash ratio of 1.50x.

However, profitability remains deeply negative with return on equity at -123.6% and return on invested capital at -33.7%.

Cash generation is still weak, with free cash flow yield at -10.6% and operating cash flow yield negative.

Operational Risk

Gross margin is strong at 84.1%, indicating the core business can still generate healthy unit economics.

But operating performance is poor, with EBIT margin at -210.4% and operating cash flow margin at -213.4%.

Working capital efficiency is strained by 162.7 days of sales outstanding and a cash conversion cycle of -153.2 days.

Inventory turnover is moderate at 3.15x, but the overall operating cycle remains long at 278.4 days.

Valuation Risk

The stock screens expensive on sales at 20.7x and book value at 8.8x.

Negative earnings and cash flow make traditional earnings and FCF multiples less meaningful, but they still signal a valuation that depends on a turnaround.

Enterprise value to sales remains elevated at 19.8x despite weak current profitability.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Ascentage Pharma Group International. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →